Evolus, Inc. (EOLS): Total Assets
$225.87M
As of 2025-12-31
$248.02M
As of 2026-06-30
+8.3%
3-year compound annual growth
+1.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $225.87M | -2.9% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $232.57M | +23.1% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $189.00M | +6.2% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $177.98M | -30.9% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $257.48M | +23.2% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $209.07M | -13.0% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $240.44M | +39.9% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $171.84M | +12.9% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $152.23M | n/a | 2019-03-20, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 2025-12-31 | $225.87M | -2.9% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $396.90M | +13.1% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $383.53M | +18.7% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $826.14M | +595.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $399.48M | +2.7% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $817.15M | +193.0% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.56B | +65.7% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $717.90M | -34.2% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $726.16M | -11.8% |
Compare EOLS, IRWD, XERS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗